cardiology

Drinking Half to One Glass of Wine Daily Linked to 50% Lower Heart Complication Risk

by

Moderate wine consumption, measured via biomarkers, is linked to a 38-50% reduction in cardiovascular risks, according to a University of Barcelona-led study. However, excessive drinking eliminates these benefits, and more research is needed to confirm causality and explore mechanisms. Moderate wine consumption may lower cardiovascular risks by up to 50%, but more studies are needed … Read more

NIH Scientists Unmask the Hidden Secrets of “Bad” Cholesterol

by

NIH scientists visualized how LDL binds to its receptor, identifying mutations causing cholesterol buildup and heart disease. Their findings, published in Nature, could improve personalized treatments and lead to new cholesterol-lowering drugs. The findings could lead to more tailored treatments for cardiovascular disease. Scientists at the National Institutes of Health (NIH) have achieved a critical … Read more

A New Era of Early Detection and Precision

by

Fast, accurate diagnosis of multiple sclerosis (MS) can be life-changing for patients, and new updates to the existing criteria are aiming to make that possible, ensuring that those living with the condition get the treatment they need when it matters most. Building on decades of research and clinical experience, the McDonald diagnostic criteria have served … Read more

L-Arginine supplementation as mitochondrial therapy in diabetic cardiomyopathy | Cardiovascular Diabetology

by

Huo JL, Feng Q, Pan S, Fu WJ, Liu Z, Liu Z. Diabetic cardiomyopathy: early diagnostic biomarkers, pathogenetic mechanisms, and therapeutic interventions. Cell Death Discov. 2023;9(1):256. Article  CAS  PubMed  PubMed Central  Google Scholar  Grubic Rotkvic P, Planinic Z, Liberati Prso AM, Sikic J, Galic E, Rotkvic L. The Mystery of Diabetic Cardiomyopathy: from early concepts … Read more

SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives | Cardiovascular Diabetology

by

Zinman B, et al. Cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28. https://doi.org/10.1056/NEJMoa1504720. Empagliflozin. Article  CAS  PubMed  Google Scholar  Mahaffey KW, et al. Canagliflozin for primary and Secondary Prevention of Cardiovascular Events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137:323–34. https://doi.org/10.1161/CIRCULATIONAHA.117.032038. Article  CAS  PubMed  PubMed Central  Google … Read more